Michael Hageman

Michael Hageman
  • Valentino J. Stella Distinguished Professor
  • Director, Biopharmaceutical Innovation & Optimization Center

Contact Info

Simons, Room 274
2093 Constant Avenue
Lawrence, KS 66047


Ph.D. in Pharmaceutical Chemistry, University of Kansas, Lawrence, KS
M.S. in Pharmaceutical Chemistry, University of Kansas, Lawrence, KS
B.S. in Pharmacy, University of Kansas, Lawrence, KS


Prior to joining KU's Department of Pharmaceutical Chemistry, Hageman spent more than 30 years in the pharmaceutical industry. He has extensive experience in physicochemical characterization and preclinical assessment of new chemical entities (NCE), including proteins, peptides, oligonucleotides, protein drug conjugates, prodrugs and other small molecule based therapeutics.

He has been directly involved in the discovery process with chemical lead selection, chemical lead optimization and drug candidate selection for transition into clinical development. Those pre-clinical experiences include drug delivery research for both parenteral and oral dosage form design, with particular emphasis on designing specialized formulation strategies to overcome poor drug stability and poor aqueous solubility and the ultimate goal of enhancing developability and commercialization.

Hageman also has extensive experience and resulting patents on the generation of solublilzed dosage forms for administration, parenteral and oral, of both immediate-release and controlled-release dosage forms. Similarly, critical experience in factors which influence processing technologies, such as lyophilization and spray drying for both biologics and small molecule NCE, provides a window to later phase manufacturing challenges.

In depth lab work uses a materials-characterization approach to understanding the fundamental role of both physicochemical and physicomechanical properties in both the chemical and physical stability within these amorphous systems, which dictate the resulting bioperformance of these systems.

He has expertise at understanding the role of polymers and excipients in both the dissolution behaviour of these solid dispersion systems and their ability to produce and maintain supersaturated drug concentrations to enhance oral absorption.